Lixte Biotechnology Warrants
LIXTW
LIXTW was delisted on the 26th of November, 2025.
0 hedge funds and large institutions have $0 invested in Lixte Biotechnology Warrants in 2025 Q4 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 0 reducing their positions, and 3 closing their positions.
1.67% less ownership
Funds ownership: 1.67% → 0% (-1.7%)
100% less funds holding
Funds holding: 3 → 0 (-3)
100% less capital invested
Capital invested by funds: $3.6K → $0 (-$3.6K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Clear Street
New York
|
-$3.12K |
| 2 |
NFSG
Newbridge Financial Services Group
Boca Raton,
Florida
|
-$361 |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$125 |
LIXTW Hedge Fund Activity: Q4 2025 in Review
0 of the 8,229 institutional investors tracked by Wall St. Rank reported a position in Lixte Biotechnology Warrants (LIXTW) for Q4 2025, worth a combined $0 — down 100% from $3.6K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of LIXTW and 0 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Clear Street, exiting entirely with an estimated $3.12K sold.
- 0 institutional investors held Lixte Biotechnology Warrants (LIXTW) as of Q4 2025, down from 3 in Q3 2025.
- Funds reported $0 of Lixte Biotechnology Warrants stock for Q4 2025, down 100% quarter-over-quarter.
- 0 funds opened new Lixte Biotechnology Warrants positions in Q4 2025 and 3 closed out, a net change of -3 holders.
- The largest Lixte Biotechnology Warrants seller in Q4 2025 was Clear Street, an estimated $3.12K sold.
Based on aggregated 13F filings for Q4 2025.